查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2000754

新冠疫苗市场：2026-2032年全球市场预测（依疫苗技术、剂量方案、包装、给药途径、通路及最终用户划分）

COVID-19 Vaccines Market by Vaccine Technology, Dosage Regimen, Packaging Type, Application Route, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，新冠肺炎疫苗市场价值将达到 2,601 亿美元，到 2026 年将成长至 2,853 亿美元，到 2032 年将达到 5,435.7 亿美元，复合年增长率为 11.10%。

主要市场统计数据
基准年 2025 2601亿美元
预计年份：2026年 2853亿美元
预测年份：2032年 5435.7亿美元
复合年增长率 (%) 11.10%

对新冠疫苗生态系统的变革进行权威解读，重点在于科学进步、监管调整和系统韧性。

全球应对新冠疫情的行动永久重塑了整个医疗卫生生态系统中疫苗研发、公共卫生运作和商业性考量的模式。过去几年，科学发现以前所未有的速度加速发展，推动了新型疫苗平台的涌现，同时也丰富了传统疫苗的研发方法。同时，监管的紧迫性和严格的安全监测共同为适应性临床实验室设计和分阶段核准流程树立了新的先例。这些变化改变了製造商、支付者和医疗服务提供者评估风险、分配资源和确定投资优先顺序的方式。

科学平台的多元化、供应链的演变以及人们的行为，是如何从根本上重塑我们用于提供 COVID-19 疫苗的策略方法的？

目前新冠疫苗接种领域正经历多项变革性变化，这些变化持续影响所有相关人员的策略决策。传讯RNA技术的科学成熟不仅展现了其快速应对新出现的变异株的能力，也影响未来疫苗研发平台的选择。同时，蛋白质次单元製剂的改进，包括优化的佐剂系统，为需要不同安全性和反应原性特征的人提供了更多选择。这些并行发展丰富了产品平臺，并为生产商和采购商拓宽了策略选择。

2025 年的关税环境将鼓励采购多元化、降低供应链风险，并促进对整个疫苗价值链国内製造业的投资。

2025年关税及相关贸易措施的实施，为疫苗采购和分发的动态增添了复杂因素，影响了成本结构、筹资策略和营运计画。关税调整波及整个价值链的投入要素，包括无菌生产所需的特殊原料、一次性生产组件和包装材料。这些调整促使采购团队重新评估其供应商组合，探索替代筹资策略，并更重视近岸外包和区域製造伙伴关係，以降低跨境成本波动带来的风险。

从多维细分观点，将平台科学、管理策略、管理途径、包装、通路、终端用户群和采购模式连结起来。

精细化的市场区隔架构明确了产品开发、管理策略和商业性策略应如何协调一致，以满足多样化的需求。就疫苗技术而言，灭活疫苗、mRNA疫苗和蛋白质次单元平台之间的差异至关重要，因为每个管道都需要不同的开发流程、製造地和低温运输能力。特别是蛋白质次单元疫苗，又可进一步细分为佐剂型和非佐剂型，这会影响其免疫抗原性特征和对目标族群的适用性。就接种方案而言，加强针、单剂和双剂接种策略的差异会影响方案设计、合规性考量，并改变采购团队的供应预测。就给药途径而言，肌肉注射和鼻腔给药的选择决定了给药基础设施的要求，并可能影响特定族群的接受度。

政策框架、生产能力和分销模式方面的区域差异如何影响了获取和实施 COVID-19 疫苗的针对性方法？

区域趋势持续对疫苗政策、分销基础设施和商业性模式产生重大影响，认识到这些差异对于制定有效策略至关重要。在美洲，大规模的公共采购项目与透过临床和药房管道产生的大量私人需求并存，从而形成了一种强调灵活供应合约和健全低温运输物流的双重分销模式。法规环境支持已建立的紧急使用授权机制和分阶段实施的标准化上市后监测实践，而公共卫生宣传活动则日益侧重于加强免疫接种推广和儿童接种策略。

疫苗研发公司、契约製造和物流合作伙伴之间的策略行动：合作、扩大模组化生产能力和分销管道多元化。

新冠疫苗领域的企业展现出广泛的策略性倡议，涵盖平台创新、分阶段配方改进、以产能为导向的伙伴关係以及多元化的分销管道。领先的生物製药公司持续投资新一代疫苗平台和佐剂系统，以扩大目标族群并提升安全性和耐受性。同时，契约製造组织（CMO）和低温运输物流专家正在加强与疫苗研发者的合作，扩大灌装和包装流程的产能，并着手解决先前阻碍疫苗快速部署的瓶颈问题。

为提高疫苗利害关係人的生产柔软性、低温运输透明度、监管合作和通路特定准入策略，采取切实可行的策略措施。

产业领导者可以透过将策略投资与营运实际情况和公共卫生目标结合，来提高策略投资的有效性。首先，优先发展能够适应多种平台和剂型的灵活生产能力，可以缩短新配方的部署时间，并支援对新出现的变体做出快速反应。其次，透过数位化追踪和整合物流伙伴关係，增强端对端低温运输的可视性，可以最大限度地减少废弃物，并改善分配决策，尤其是在储存基础设施有限的情况下。第三，与监管机构建立合作关係，重点关注针对特定人群（例如青少年和儿童）的明确证据要求，可以简化核准流程，并增强人们对相关项目的信心。

采用严谨的混合方法研究途径，结合相关人员访谈、监管和临床证据审查，并透过供应链用例进行检验。

本研究整合了一手和二手证据，建构了新冠疫苗现状的全面图像。一手资料包括对生产、物流、监管事务和公共卫生管理等环节的相关人员进行的结构化访谈，从而获得关于营运挑战和策略应对的第一手观点。二手资料包括同侪审查文献、提交给公共监管机构的文件、临床实验室註册资讯和产业技术报告，以确保事实依据和论点的交叉检验。关于分销和采购实践的数据透过供应链流程图和案例研究进行交叉检验，这些案例研究重点突出了实际营运中汲取的经验教训。

前瞻性的综合分析强调，需要将科学创新、有韧性的营运结构和协调一致的措施结合起来，以确保疫苗计画的长期成功。

随着全球社会逐渐走出疫情初期紧急阶段，新冠疫苗生态系统正迈向一个更为复杂和成熟的阶段，科学创新、卓越营运和政策一致性将决定其长期成效。新型疫苗平台、不断演进的给药策略和多元化的供应模式的相互作用，为提升人群保护水平、同时解决公平性和可及性问题提供了多种途径。然而，要抓住这些机会，需要持续投资于可扩展的生产製造、更聪明的采购方式以及持续的公众参与，以维持公众信心和疫苗接种率。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：新冠疫苗市场：依疫苗技术划分

  • 失活
  • mRNA
  • 蛋白质次单元
    • 佐剂类型
    • 非辅助型

第九章：新冠疫苗市场：依剂量方案划分

  • 加强剂量
  • 1. 接种疫苗
  • 两剂疫苗

第十章：新冠疫苗市场：依包装类型划分

  • 预填充式注射器
  • 管瓶

第十一章：新冠疫苗市场：依给药途径划分

  • 肌肉内部
  • 鼻内

第十二章：新冠疫苗市场：依通路划分

  • 诊所
  • 医院
  • 药局

第十三章：新冠肺炎疫苗市场：依最终用户划分

  • 青少年
  • 成人
  • 儿童

第十四章：新冠肺炎疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：新冠疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：新冠肺炎疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国新冠疫苗市场

第十八章：中国新冠疫苗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AIVITA Biomedical Inc.
  • AstraZeneca Plc
  • Baseimmune Ltd.
  • Bharat BIoTech International Ltd.
  • Biological E. Ltd.
  • CanSino Biologics Inc.
  • Centivax Inc.
  • Codagenix Inc.
  • CureVac SE
  • Dr. Reddy's Laboratories Ltd.
  • Emergex Vaccines Holding Ltd.
  • Etherna Immunotherapies Nv
  • Gennova Biopharmaceuticals Ltd.
  • GlaxoSmithKline plc.
  • HDT Bio, Inc.
  • Meissa Vaccines, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax Inc.
  • Osivax SAS
  • Pfizer Inc.
  • Providence Therapeutics Inc.
  • SANOFI
  • Serum Institute of India Pvt. Ltd.
  • Sinovac BIoTech Ltd.
  • Vaccitech PLC
  • Zydus Lifesciences Ltd.
Product Code: MRR-02026C4C976F

The COVID-19 Vaccines Market was valued at USD 260.10 billion in 2025 and is projected to grow to USD 285.30 billion in 2026, with a CAGR of 11.10%, reaching USD 543.57 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 260.10 billion
Estimated Year [2026] USD 285.30 billion
Forecast Year [2032] USD 543.57 billion
CAGR (%) 11.10%

An authoritative orientation to the transformed COVID-19 vaccine ecosystem highlighting scientific acceleration, regulatory adaptation, and system-level resilience

The global response to COVID-19 has permanently reshaped vaccine development paradigms, public health operations, and commercial considerations across the healthcare ecosystem. Over the past years, scientific discovery accelerated at an unprecedented pace, catalyzing novel vaccine platforms alongside traditional approaches. Simultaneously, the interplay between regulatory urgency and rigorous safety oversight created new precedents for adaptive clinical trial design and rolling submission pathways. These shifts have changed how manufacturers, payers, and providers evaluate risk, allocate resources, and prioritize investments.

Against this backdrop, supply chain resilience emerged as a strategic priority, intersecting cold chain logistics, raw material sourcing, and contract manufacturing capacity. Public health demand patterns evolved as populations experienced heterogeneous rates of vaccine uptake, booster acceptance, and variant-driven needs, prompting programmatic adjustments. Market entrants and incumbents alike must now operate within a landscape where scientific innovation coexists with complex distribution requirements and heightened public scrutiny. Consequently, the industry's next phase emphasizes scalable manufacturing, transparent communication strategies, and policy alignment to sustain immunization programs and maintain public trust.

How scientific platform diversification, supply chain evolution, and public behavior are fundamentally reshaping strategic approaches to COVID-19 vaccination delivery

The landscape of COVID-19 vaccination is defined by several transformative shifts that continue to influence strategic decision-making across stakeholders. Scientific maturation of messenger RNA technology has not only demonstrated rapid response capability against emerging variants but has also influenced platform selection for future vaccine development. Concurrently, improvements in protein subunit formulations, including optimized adjuvant systems, have expanded options for populations that require different safety and reactogenicity profiles. These parallel developments have created a more diversified product pipeline and widened strategic choices for manufacturers and purchasers.

Operationally, distribution networks have adapted to balance high-throughput mass vaccination campaigns with targeted, routine delivery through clinical and pharmacy channels. Policy frameworks evolved to accommodate pandemic-era emergency measures while progressively integrating lessons into standard regulatory processes. Supply chain orchestration improved through strategic partnerships with contract manufacturers and cold chain logistics providers, yet vulnerabilities remain in specialized inputs and capacity bottlenecks. Moreover, public sentiment and behavioral dynamics around booster acceptance and pediatric immunization continue to shape demand signals, necessitating ongoing engagement strategies that combine transparent evidence communication with tailored access programs.

The 2025 tariff environment catalyzing sourcing diversification, supply chain de-risking, and domestic manufacturing investment across the vaccine value chain

The imposition of tariffs and related trade measures in 2025 has added a complex layer to vaccine procurement and distribution dynamics, influencing cost profiles, sourcing strategies, and operational planning. Tariff changes affected inputs across the value chain, including specialized raw materials, single-use manufacturing components, and packaging supplies that are critical to sterile production. These adjustments prompted procurement teams to reassess supplier portfolios, seek alternative sourcing strategies, and increase emphasis on nearshoring or regional manufacturing partnerships to reduce exposure to cross-border cost volatility.

In response to heightened tariff risk, supply chain managers intensified supplier qualification processes and pursued contractual protections to insulate production continuity. Cold chain logistics providers and contract manufacturers recalibrated pricing models to reflect the incremental costs and administrative burdens associated with cross-border movements. At the same time, health systems and public purchasers evaluated procurement models with more pronounced scrutiny on total landed cost, lead times, and supply guarantees. The tariff landscape also incentivized investment in domestic fill-and-finish capacity and partnerships that prioritized geographic diversification, thereby improving strategic resilience but requiring capital allocation and longer-term planning.

A multi-dimensional segmentation perspective connecting platform science, dosage strategy, delivery route, packaging, distribution channels, end-user cohorts, and procurement models

A granular segmentation framework clarifies where product development, delivery strategies, and commercial approaches must be tailored to meet heterogeneous needs. Based on Vaccine Technology, distinctions among Inactivated, mRNA, and Protein Subunit platforms matter because each pathway demands different development timelines, manufacturing footprints, and cold chain capabilities; notably, Protein Subunit vaccines are further delineated between Adjuvanted and Non Adjuvanted formulations, which influence immunogenicity profiles and target population suitability. Based on Dosage Regimen, differences across Booster Dose, Single Dose, and Two Dose strategies drive programmatic design, influence adherence considerations, and alter supply forecasting horizons for procurement teams. Based on Application Route, the choice between Intramuscular and Intranasal delivery defines administration infrastructure needs and can affect acceptance rates among specific populations.

Further segmentation based on Packaging Type-Prefilled Syringe versus Vial-has operational implications for wastage rates, administration speed in mass clinics, and cold chain volume planning. Distribution Channel segmentation spanning Clinic, Hospital, and Pharmacy underscores the necessity of channel-specific engagement models and reimbursement considerations. End User segmentation across Adolescent, Adult, and Child cohorts requires tailored clinical evidence packages, safety communications, and dosing strategies to achieve uptake targets. Finally, Procurement Model segmentation between Government Procurement and Private Purchase shapes pricing negotiations, contracting structures, and access pathways, thereby influencing how manufacturers structure commercial offers and manage channel partnerships. Together, these segmentation lenses enable stakeholders to match product attributes to operational realities and population needs.

How differentiated regional policy frameworks, manufacturing capacity, and distribution models are shaping targeted approaches to COVID-19 vaccine access and program execution

Regional dynamics continue to exert significant influence on vaccine policy, distribution infrastructure, and commercial approaches, and recognizing these differences is essential to effective strategy formation. In the Americas, large public procurement programs coexist with substantial private demand through clinical and pharmacy channels, leading to a dual-track distribution model that emphasizes flexible supply agreements and robust cold chain logistics. The regulatory environment favors established emergency authorization mechanisms and progressive alignment toward standardized post-market surveillance practices, while public health campaigns increasingly focus on booster outreach and pediatric dosing strategies.

In Europe, Middle East & Africa, the landscape is more heterogeneous, with advanced regulatory systems in some markets and capacity constraints in others. This diversity drives strategies that combine regional manufacturing hubs, targeted deployment programs, and tailored financing mechanisms to improve access. Public-private partnerships and international procurement consortia play a pivotal role in addressing inequities and logistical gaps. In Asia-Pacific, rapid manufacturing scale-up capabilities, a growing contract manufacturing ecosystem, and diverse regulatory timelines create both opportunities and complexity for market entrants. Regional players emphasize supply reliability, competitive pricing, and the ability to support large-scale immunization campaigns, while also navigating evolving local regulatory expectations and distribution modalities. Across all regions, collaboration between policymakers, manufacturers, and service providers remains a critical enabler of effective vaccine program implementation.

Strategic behaviors among vaccine developers, contract manufacturers, and logistics partners revealing collaboration, modular capacity expansion, and channel diversification

Companies operating in the COVID-19 vaccine space demonstrate a range of strategic postures, from platform innovation and incremental formulation improvements to capacity-focused partnerships and diversified commercial channels. Leading biopharmaceutical firms have continued to invest in next-generation vaccine platforms and adjuvant systems to widen their addressable populations and improve safety and tolerability profiles. At the same time, contract manufacturing organizations and cold chain logistics specialists have strengthened alliances with vaccine developers to expand fill-and-finish throughput and reduce bottlenecks that previously constrained rapid deployment.

Strategic collaboration has become a dominant theme, with alliances spanning clinical research universities, biotech innovators, and global distribution partners to accelerate candidate progression while managing cost and risk. Some companies have prioritized modular manufacturing designs that facilitate rapid switching between vaccine types, whereas others have invested in regional production footprints to mitigate trade-related disruptions. Commercial strategies increasingly blend direct government contracting with pharmacy and clinic channel engagement, supported by targeted educational campaigns to address hesitancy. Overall, the competitive dynamic rewards organizations that can combine scientific agility with operational scalability and credible, transparent stakeholder communication.

Practical strategic moves for vaccine stakeholders to enhance manufacturing flexibility, cold chain visibility, regulatory engagement, and channel-specific access approaches

Industry leaders can accelerate impact by aligning strategic investments with operational realities and public health objectives. First, prioritizing flexible manufacturing capacity-capable of handling multiple platforms and dose configurations-reduces time-to-deployment for novel formulations and supports rapid response to emergent variants. Second, strengthening end-to-end cold chain visibility through digital tracking and integrated logistics partnerships minimizes wastage and improves allocation decisions, particularly in contexts with constrained storage infrastructure. Third, cultivating regulatory engagement that focuses on clear evidence requirements for specific populations, such as adolescents and children, streamlines approval pathways and bolsters program confidence.

In parallel, adopting differentiated channel strategies that recognize the distinct roles of clinics, hospitals, and pharmacies ensures broader access while addressing local administration preferences. Investment in tailored risk communication and community engagement programs can improve booster acceptance and sustain immunization momentum. Finally, exploring procurement structures that combine long-term supply commitments with options for private purchase supports both public health objectives and commercial sustainability. Together, these actions enhance resilience, support equitable access, and create a more predictable operating environment for vaccine stakeholders.

A rigorous mixed-methods research approach integrating stakeholder interviews, regulatory and clinical evidence review, and supply chain case study triangulation

This research synthesizes primary and secondary evidence to construct a comprehensive view of the COVID-19 vaccine landscape. Primary inputs included structured interviews with stakeholders across manufacturing, logistics, regulatory affairs, and public health administration, providing firsthand perspectives on operational challenges and strategic responses. Secondary inputs encompassed peer-reviewed literature, public regulatory filings, clinical trial registries, and industry technical reports to ensure factual grounding and cross-validation of claims. Data on distribution and procurement practices were triangulated through supply chain process mapping and case studies that highlight real-world implementation lessons.

Analytical methods combined qualitative thematic analysis with comparative scenario assessment to surface risks and identify resilience strategies. The methodology emphasized transparency in sourcing and reproducibility in approach, with clear documentation of interview protocols, inclusion criteria for secondary sources, and the analytical frameworks used to synthesize findings. Where appropriate, the research incorporated sensitivity checks to evaluate how changes in trade policy, variant emergence, or public acceptance could alter operational priorities. This mixed-method approach ensures that insights reflect both empirical evidence and pragmatic perspectives from practitioners.

A forward-looking synthesis that underscores the necessity of aligning scientific innovation, resilient operations, and collaborative policy to secure long-term vaccine program success

As the global community moves beyond the initial pandemic emergency phase, the COVID-19 vaccine ecosystem is settling into a more complex, mature era where scientific innovation, operational excellence, and policy coherence determine long-term outcomes. The interplay of novel platforms, evolving dosage strategies, and diversified delivery models offers multiple pathways to improve population protection while addressing equity and access concerns. However, realizing these opportunities requires continued investment in scalable manufacturing, smarter procurement practices, and sustained public engagement to maintain confidence and uptake.

Looking ahead, the capacity to integrate scientific advances with resilient supply chains and adaptive regulatory strategies will define organizational success. Stakeholders that proactively manage tariff and trade risks, invest in modular production capabilities, and tailor approaches to regional realities will be better positioned to deliver reliable access to vaccines. Ultimately, the sector's progress will depend on collaborative problem-solving across public and private actors to align incentives, share capacity, and prioritize interventions that maximize public health benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COVID-19 Vaccines Market, by Vaccine Technology

  • 8.1. Inactivated
  • 8.2. mRNA
  • 8.3. Protein Subunit
    • 8.3.1. Adjuvanted
    • 8.3.2. Non Adjuvanted

9. COVID-19 Vaccines Market, by Dosage Regimen

  • 9.1. Booster Dose
  • 9.2. Single Dose
  • 9.3. Two Dose

10. COVID-19 Vaccines Market, by Packaging Type

  • 10.1. Prefilled Syringe
  • 10.2. Vial

11. COVID-19 Vaccines Market, by Application Route

  • 11.1. Intramuscular
  • 11.2. Intranasal

12. COVID-19 Vaccines Market, by Distribution Channel

  • 12.1. Clinic
  • 12.2. Hospital
  • 12.3. Pharmacy

13. COVID-19 Vaccines Market, by End User

  • 13.1. Adolescent
  • 13.2. Adult
  • 13.3. Child

14. COVID-19 Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. COVID-19 Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. COVID-19 Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States COVID-19 Vaccines Market

18. China COVID-19 Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AIVITA Biomedical Inc.
  • 19.6. AstraZeneca Plc
  • 19.7. Baseimmune Ltd.
  • 19.8. Bharat Biotech International Ltd.
  • 19.9. Biological E. Ltd.
  • 19.10. CanSino Biologics Inc.
  • 19.11. Centivax Inc.
  • 19.12. Codagenix Inc.
  • 19.13. CureVac SE
  • 19.14. Dr. Reddy's Laboratories Ltd.
  • 19.15. Emergex Vaccines Holding Ltd.
  • 19.16. Etherna Immunotherapies Nv
  • 19.17. Gennova Biopharmaceuticals Ltd.
  • 19.18. GlaxoSmithKline plc.
  • 19.19. HDT Bio, Inc.
  • 19.20. Meissa Vaccines, Inc.
  • 19.21. Merck & Co., Inc.
  • 19.22. Moderna, Inc.
  • 19.23. Novavax Inc.
  • 19.24. Osivax SAS
  • 19.25. Pfizer Inc.
  • 19.26. Providence Therapeutics Inc.
  • 19.27. SANOFI
  • 19.28. Serum Institute of India Pvt. Ltd.
  • 19.29. Sinovac Biotech Ltd.
  • 19.30. Vaccitech PLC
  • 19.31. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. GCC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 140. GCC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 141. GCC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. GCC COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. G7 COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 164. G7 COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 165. G7 COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. G7 COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. NATO COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 172. NATO COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 173. NATO COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. NATO COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)